Safety Outcomes:
We combined the data retrieved from the five trials for serious adverse events (SAEs) and adverse events (AEs) such as deaths, myocardial infarctions, recurrent strokes, hernia, hemorrhage of the digestive tract, fever (>38 °C), hemorrhagic transformation at 24 hours, lung infection, urinary tract infection, herpes virus infection, abnormal laboratory liver-function test, gastrointestinal disorders, arrhythmia, and macular edema. The collected data of common AEs are displayed in Table 2. Data analysis was performed using statistical software provided by Stata16.0.We did not find any significant difference between the fingolimod and standardized treatment groups in terms of SAEs and AEs.
Table 2. Safety outcomes in the meta-analysis